Related Experiment Video
Updated: May 19, 2026
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Fucoxanthin ameliorates experimental autoimmune encephalomyelitis by inhibiting microglial NLRP3 inflammasome
Xiaoqian Dong1,2, Linlin Zhang2, Yuxin He2
1Department of Neurology, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, China. daqizhang2010@163.com.
Abstract:
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) characterized by focal inflammation, demyelination, axonal injury, and neuronal damage. Microglia-mediated neuroinflammation plays a critical role in its pathogenesis. Fucoxanthin (Fx), a compound abundant in various algae, exhibits antioxidant, anti-tumor, and anti-inflammatory properties. This study aimed to investigate the therapeutic effects and underlying mechanisms of Fx in ameliorating experimental autoimmune encephalomyelitis (EAE), a well-established animal model of MS. Our results demonstrated that Fx significantly attenuated inflammatory cell infiltration, demyelination, and activation of pro-inflammatory M1-polarized microglia in the spinal cords of EAE mice. Moreover, we found that Fx exerted anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and subsequent pyroptosis in microglia, both in EAE mice and in BV2 microglial cells. In summary, Fx exhibited a promising therapeutic effect on EAE by suppressing neuroinflammation through inhibition of microglial M1 polarization and NLRP3 inflammasome-mediated pyroptosis. Thus, Fx may represent a potential therapeutic agent for the treatment of MS.
Insights
Fucoxanthin (Fx) shows promise for treating multiple sclerosis (MS) by reducing neuroinflammation and microglial activation in an animal model. It inhibits key inflammatory pathways, suggesting potential therapeutic benefits for MS patients.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a CNS autoimmune disease driven by neuroinflammation, particularly involving microglia.
- Fucoxanthin (Fx), an algal compound, possesses known anti-inflammatory and antioxidant properties.
Purpose of the Study:
- To evaluate the therapeutic potential of Fx in experimental autoimmune encephalomyelitis (EAE), an MS animal model.
- To elucidate the mechanisms by which Fx modulates neuroinflammation in MS.
Main Methods:
- Administration of Fx to EAE mice and treatment of BV2 microglial cells.
- Assessment of inflammatory cell infiltration, demyelination, and microglial polarization in spinal cords.
- Analysis of NLRP3 inflammasome activation and pyroptosis in microglia.
Main Results:
- Fx significantly reduced inflammation, demyelination, and M1 microglial polarization in EAE mice.
- Fx inhibited NLRP3 inflammasome activation and pyroptosis in both EAE mice and BV2 cells.
- Fx demonstrated neuroprotective effects by suppressing microglial-driven neuroinflammation.
Conclusions:
- Fucoxanthin exhibits significant therapeutic effects against EAE by suppressing M1 microglial polarization and NLRP3 inflammasome-mediated pyroptosis.
- Fx represents a potential novel therapeutic agent for managing multiple sclerosis.
- Targeting microglial activation and inflammasome pathways with Fx offers a promising strategy for MS treatment.
